These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Treatment of vitiligo with narrowband-UVB (TL01) combined with tacrolimus ointment (0.1%) vs. placebo ointment, a randomized right/left double-blind comparative study. Nordal EJ; Guleng GE; Rönnevig JR J Eur Acad Dermatol Venereol; 2011 Dec; 25(12):1440-3. PubMed ID: 21466589 [TBL] [Abstract][Full Text] [Related]
43. Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study. Thaçi D; Reitamo S; Gonzalez Ensenat MA; Moss C; Boccaletti V; Cainelli T; van der Valk P; Buckova H; Sebastian M; Schuttelaar ML; Ruzicka T; Br J Dermatol; 2008 Dec; 159(6):1348-56. PubMed ID: 18782319 [TBL] [Abstract][Full Text] [Related]
44. Tacrolimus ointment is safe and effective in the treatment of atopic dermatitis: results in 8000 patients. Koo JY; Fleischer AB; Abramovits W; Pariser DM; McCall CO; Horn TD; Gottlieb AB; Jaracz E; Rico MJ J Am Acad Dermatol; 2005 Aug; 53(2 Suppl 2):S195-205. PubMed ID: 16021175 [TBL] [Abstract][Full Text] [Related]
45. A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids. Murrell DF; Calvieri S; Ortonne JP; Ho VC; Weise-Riccardi S; Barbier N; Paul CF Br J Dermatol; 2007 Nov; 157(5):954-9. PubMed ID: 17935515 [TBL] [Abstract][Full Text] [Related]
46. Effectiveness and safety of topical tacrolimus monotherapy for repigmentation in vitiligo: a comprehensive literature review. Sisti A; Sisti G; Oranges CM An Bras Dermatol; 2016 Apr; 91(2):187-95. PubMed ID: 27192518 [TBL] [Abstract][Full Text] [Related]
47. A randomized study of the safety, absorption and efficacy of pimecrolimus cream 1% applied twice or four times daily in patients with atopic dermatitis. Ling M; Gottlieb A; Pariser D; Caro I; Stewart D; Scott G; Abrams K J Dermatolog Treat; 2005 Aug; 16(3):142-8. PubMed ID: 16096179 [TBL] [Abstract][Full Text] [Related]
48. Health-related utility among adults with atopic dermatitis treated with 0.1% tacrolimus ointment as maintenance therapy over the long term: findings from the Protopic CONTROL study. Poole CD; Chambers C; Sidhu MK; Currie CJ Br J Dermatol; 2009 Dec; 161(6):1335-40. PubMed ID: 19754867 [TBL] [Abstract][Full Text] [Related]
49. Tacrolimus ointment in the treatment of occupationally induced chronic hand dermatitis. Schliemann S; Kelterer D; Bauer A; John SM; Skudlik C; Schindera I; Wehrmann W; Elsner P Contact Dermatitis; 2008 May; 58(5):299-306. PubMed ID: 18416762 [TBL] [Abstract][Full Text] [Related]
50. An open label study to compare the efficacy of topical mometasone furoate with topical placental extract versus topical mometasone furoate with topical tacrolimus in patients with vitiligo involving less than 10% body surface area. Shrestha S; Jha AK; Thapa DP; Bhattarai CK; Ghimire A Nepal Med Coll J; 2014 Sep; 16(1):1-4. PubMed ID: 25799800 [TBL] [Abstract][Full Text] [Related]
51. Effectiveness of 0.1% topical tacrolimus in adult and children patients with vitiligo. Udompataikul M; Boonsupthip P; Siriwattanagate R J Dermatol; 2011 Jun; 38(6):536-40. PubMed ID: 21352308 [TBL] [Abstract][Full Text] [Related]
52. Topical 0.05% clobetasol propionate versus 1% pimecrolimus ointment in vitiligo. Coskun B; Saral Y; Turgut D Eur J Dermatol; 2005; 15(2):88-91. PubMed ID: 15757818 [TBL] [Abstract][Full Text] [Related]
53. Tacalcitol and narrow-band phototherapy in patients with vitiligo. Leone G; Pacifico A; Iacovelli P; Paro Vidolin A; Picardo M Clin Exp Dermatol; 2006 Mar; 31(2):200-5. PubMed ID: 16487090 [TBL] [Abstract][Full Text] [Related]
54. Narrow-band UVB for the treatment of vitiligo: an emerging effective and well-tolerated therapy. Kanwar AJ; Dogra S; Parsad D; Kumar B Int J Dermatol; 2005 Jan; 44(1):57-60. PubMed ID: 15663664 [TBL] [Abstract][Full Text] [Related]
55. Long-term treatment with 0.1% tacrolimus ointment in adults with atopic dermatitis: results of a two-year, multicentre, non-comparative study. Reitamo S; Ortonne JP; Sand C; Bos J; Cambazard F; Bieber T; Grønhøj-Larsen C; Rustin M; Fölster-Holst R; Schuttelaar M; Acta Derm Venereol; 2007; 87(5):406-12. PubMed ID: 17721647 [TBL] [Abstract][Full Text] [Related]
56. Sustained efficacy and safety of pimecrolimus cream 1% when used long-term (up to 26 weeks) to treat children with atopic dermatitis. Langley RG; Eichenfield LF; Lucky AW; Boguniewicz M; Barbier N; Cherill R Pediatr Dermatol; 2008; 25(3):301-7. PubMed ID: 18577032 [TBL] [Abstract][Full Text] [Related]
57. Tacrolimus ointment vs steroid ointment for eyelid dermatitis in patients with atopic keratoconjunctivitis. Nivenius E; van der Ploeg I; Jung K; Chryssanthou E; van Hage M; Montan PG Eye (Lond); 2007 Jul; 21(7):968-75. PubMed ID: 16680103 [TBL] [Abstract][Full Text] [Related]
58. Topical tacrolimus for repigmentation of vitiligo. Grimes PE; Soriano T; Dytoc MT J Am Acad Dermatol; 2002 Nov; 47(5):789-91. PubMed ID: 12399778 [TBL] [Abstract][Full Text] [Related]
59. Efficacy and safety of fire needle therapy in treating non-segmental stable vitiligo: A randomized self-controlled clinical trial. Wang Y; Lin M; Huang F; Jia R; Xu W; He Q; Xiong Q; Hu Q; Diao Q; Liu Z J Cosmet Dermatol; 2024 Oct; 23(10):3335-3346. PubMed ID: 38894565 [TBL] [Abstract][Full Text] [Related]
60. Tacrolimus ointment is effective for facial and intertriginous psoriasis. Lebwohl M; Freeman AK; Chapman MS; Feldman SR; Hartle JE; Henning A; J Am Acad Dermatol; 2004 Nov; 51(5):723-30. PubMed ID: 15523350 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]